

# Vathany Kulasingam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/292198/publications.pdf>

Version: 2024-02-01

84  
papers

3,534  
citations

201674

27  
h-index

144013

57  
g-index

87  
all docs

87  
docs citations

87  
times ranked

6108  
citing authors

#	ARTICLE	IF	CITATIONS
1	Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 588-599.	4.3	663
2	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 1244-1246.	27.0	456
3	Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 1997-2011.	3.8	179
4	Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 371-378.	28.4	140
5	Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2746-2758.	3.8	124
6	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3980-3989.	4.7	120
7	Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	112
8	Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 661-669.	3.8	107
9	Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. <i>Clinical Biochemistry</i> , 2013, 46, 399-410.	1.9	98
10	Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?. <i>Clinical Chemistry</i> , 2016, 62, 1054-1060.	3.2	87
11	Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays. <i>Journal of Proteome Research</i> , 2010, 9, 6678-6688.	3.7	78
12	Product Ion Monitoring Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap. <i>Journal of Proteome Research</i> , 2008, 7, 640-647.	3.7	73
13	Tissue culture-based breast cancer biomarker discovery platform. <i>International Journal of Cancer</i> , 2008, 123, 2007-2012.	5.1	66
14	Interlaboratory Reproducibility of Selective Reaction Monitoring Assays Using Multiple Upfront Analyte Enrichment Strategies. <i>Journal of Proteome Research</i> , 2012, 11, 3986-3995.	3.7	62
15	Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 9-14.	5.1	55
16	Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. <i>Clinical Biochemistry</i> , 2013, 46, 1462-1468.	1.9	50
17	Urinary adenosine excretion in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F184-F191.	2.7	46
18	Pediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas® 6000 analyzer: A CALIPER pilot study. <i>Clinical Biochemistry</i> , 2010, 43, 1045-1050.	1.9	44

#	ARTICLE	IF	CITATIONS
19	Nipple Aspirate Fluid Proteome of Healthy Females and Patients with Breast Cancer. <i>Clinical Chemistry</i> , 2010, 56, 848-855.	3.2	42
20	Targeted Selected Reaction Monitoring Mass Spectrometric Immunoassay for Insulin-like Growth Factor 1. <i>PLoS ONE</i> , 2013, 8, e81125.	2.5	40
21	False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125. <i>Clinical Chemistry</i> , 2014, 60, 381-388.	3.2	38
22	Recycling of the Membrane-anchored Chemokine, CX3CL1. <i>Journal of Biological Chemistry</i> , 2005, 280, 19858-19866.	3.4	37
23	Deciphering the peptidome of urine from ovarian cancer patients and healthy controls. <i>Clinical Proteomics</i> , 2014, 11, 23.	2.1	37
24	Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100155.	3.8	36
25	Deciphering the ovarian cancer ascites fluid peptidome. <i>Clinical Proteomics</i> , 2014, 11, 13.	2.1	35
26	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1333-1340.	2.5	35
27	Rapid determination of tacrolimus and sirolimus in whole human blood by direct coupling of solid-phase microextraction to mass spectrometry via microfluidic open interface. <i>Analytica Chimica Acta</i> , 2021, 1144, 53-60.	5.4	33
28	Analytical evaluation of the VITROSÂ® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals. <i>Clinical Biochemistry</i> , 2010, 43, 1039-1044.	1.9	31
29	Emerging role of clinical mass spectrometry in pathology. <i>Journal of Clinical Pathology</i> , 2020, 73, 61-69.	2.0	30
30	Extracellular Matrix Injury of Kidney Allografts in Antibody-Mediated Rejection: A Proteomics Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2705-2724.	6.1	29
31	Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2568-2574.	2.5	26
32	Fascin-1 is a novel biomarker of aggressiveness in some carcinomas. <i>BMC Medicine</i> , 2013, 11, 53.	5.5	25
33	Circulating Tumor DNA for Early Cancer Detection. <i>Journal of Applied Laboratory Medicine</i> , 2018, 3, 300-313.	1.3	25
34	From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. <i>Biomarkers in Medicine</i> , 2012, 6, 613-625.	1.4	24
35	Quantitative mass spectrometry-based assay development and validation: From small molecules to proteins. <i>Clinical Biochemistry</i> , 2013, 46, 444-455.	1.9	24
36	Evaluation of a coated blade spray-tandem mass spectrometry assay as a new tool for the determination of immunosuppressive drugs in whole blood. <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 5067-5076.	3.7	24

#	ARTICLE	IF	CITATIONS
37	Ovarian Cancer Biomarkers. <i>Advances in Clinical Chemistry</i> , 2014, , 25-77.	3.7	20
38	Towards personalized tumor markers. <i>Npj Precision Oncology</i> , 2017, 1, 17.	5.4	20
39	Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2175-2183.	1.0	19
40	Serum metabolic fingerprinting of psoriasis and psoriatic arthritis patients using solid-phase microextractionâ€”liquid chromatographyâ€”high-resolution mass spectrometry. <i>Metabolomics</i> , 2021, 17, 59.	3.0	19
41	Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 57-65.	1.3	18
42	Accuracy of Testosterone Concentrations in Compounded Testosterone Products. <i>Journal of Sexual Medicine</i> , 2015, 12, 1381-1388.	0.6	17
43	Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. <i>Clinical Biochemistry</i> , 2020, 86, 1-7.	1.9	17
44	Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay. <i>Viruses</i> , 2021, 13, 962.	3.3	17
45	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 1849-1860.	4.0	16
46	Effectiveness of the Risk of Malignancy Index and the Risk of Ovarian Malignancy Algorithm in a Cohort of Women With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 809-814.	2.5	15
47	Major milestones in translational oncology. <i>BMC Medicine</i> , 2016, 14, 110.	5.5	15
48	Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. <i>F1000Research</i> , 2017, 6, 1832.	1.6	15
49	Advances in mass spectrometry-based technologies to direct personalized medicine in ovarian cancer. <i>Translational Proteomics</i> , 2013, 1, 74-86.	1.2	13
50	Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer. <i>F1000Research</i> , 2017, 6, 1832.	1.6	13
51	Metabolomics Studies in Psoriatic Disease: A Review. <i>Metabolites</i> , 2021, 11, 375.	2.9	13
52	Prospective observational study and serosurvey of SARS-CoV-2 infection in asymptomatic healthcare workers at a Canadian tertiary care center. <i>PLoS ONE</i> , 2021, 16, e0247258.	2.5	12
53	Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course. <i>Clinical Biochemistry</i> , 2021, 90, 1-7.	1.9	11
54	Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 771-777.	2.3	11

#	ARTICLE	IF	CITATIONS
55	Validating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurements. <i>Clinical Biochemistry</i> , 2012, 45, 1533-1535.	1.9	10
56	The Use of Targeted Therapies for Precision Medicine in Oncology. <i>Clinical Chemistry</i> , 2016, 62, 1556-1564.	3.2	10
57	Ovarian cancer biomarkers: current state and future implications from high-throughput technologies. <i>Advances in Clinical Chemistry</i> , 2014, 66, 25-77.	3.7	10
58	CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. <i>Clinical Biochemistry</i> , 2012, 45, 1543-1546.	1.9	9
59	Defining appropriate utilization of AST testing. <i>Clinical Biochemistry</i> , 2020, 79, 75-77.	1.9	9
60	Immuno-Mass Spectrometry: Quantification of Low-Abundance Proteins in Biological Fluids. <i>Methods in Molecular Biology</i> , 2011, 728, 207-218.	0.9	9
61	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 19-28.	0.5	8
62	SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study. <i>Scientific Reports</i> , 2021, 11, 22428.	3.3	8
63	Disrupting the DREAM transcriptional repressor complex induces apolipoprotein overexpression and systemic amyloidosis in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	7
64	Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden. <i>F1000Research</i> , 2021, 10, 509.	1.6	6
65	Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. <i>Biological Chemistry</i> , 2007, 388, 1113-1119.	2.5	5
66	Genomic profiling for copy number changes in plasma of ovarian cancer patients – a new era for cancer diagnostics?. <i>BMC Medicine</i> , 2016, 14, 186.	5.5	5
67	Modification of the Glucose Correction Factor by Peritoneal Dialysis Solution Type in the Peritoneal Equilibration Test. <i>Peritoneal Dialysis International</i> , 2010, 30, 647-650.	2.3	4
68	Proteomic and genomic technologies for biomarker discovery. <i>Clinical Proteomics</i> , 2006, 2, 5-11.	2.1	3
69	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. <i>F1000Research</i> , 2018, 7, 189.	1.6	3
70	Sample stability of autoantibodies: A tool for laboratory quality initiatives. <i>Clinical Biochemistry</i> , 2021, 96, 43-48.	1.9	3
71	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. <i>F1000Research</i> , 2018, 7, 189.	1.6	3
72	Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. <i>Clinical Biochemistry</i> , 2020, 86, 56-60.	1.9	2

#	ARTICLE	IF	CITATIONS
73	Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000Research, 2020, 9, 732.	1.6	2
74	What Is Really in This Weight Loss Supplement?. journal of applied laboratory medicine, The, 2019, 4, 270-273.	1.3	1
75	To skim or splice? Comparing the quantification of M-proteins using two peak-integration protocols across multiple electrophoresis platforms. Clinical Biochemistry, 2022, 102, 44-49.	1.9	1
76	Multi-center evaluation of the highly sensitive Abbott ARCHITECT and Alinity thyroglobulin chemiluminescent microparticle immunoassay. Journal of Clinical Laboratory Analysis, 2022, 37, 1000000.	2.1	1
77	A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic nephrotic pattern or skewed free light chain ratio. Clinical Biochemistry, 2018, 51, 110-111.	1.9	0
78	Introduction to the Special Collection "Beating Cancer with Early Detection: A Seasoned Idea with New Insights. journal of applied laboratory medicine, The, 2018, 3, 155-158.	1.3	0
79	A Puzzling Case of Hyperviscosity Syndrome. journal of applied laboratory medicine, The, 2020, 5, 209-213.	1.3	0
80	A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. Clinical Chemistry, 2020, 66, 1373-1378.	3.2	0
81	Recurring Critical Results and Their Impact on the Volume of Critical Calls at a Tertiary Care Center. journal of applied laboratory medicine, The, 2021, 6, 962-968.	1.3	0
82	Comparing CMIA to PETINIA and Enzyme Immunoassays for Eight TDM Drugs. journal of applied laboratory medicine, The, 2021, 6, 1080-1083.	1.3	0
83	Interpretation and Clinical Value of Serum Anti-PLA2R-Antibody Testing. journal of applied laboratory medicine, The, 2021, 6, 799-803.	1.3	0
84	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, 7, 1-2.	1.3	0